Genelux (GNLX) Equity Average (2022 - 2026)
Genelux (GNLX) recorded quarterly Equity Average of $17.2 million in Q1 2026, up 14.37% quarter-over-quarter from $15.1 million in Q4 2025, and down 38.59% on a YoY basis from $28.1 million in Q1 2025.
Genelux (GNLX) Equity Average (2022 - 2026) Analysis & Trends
Genelux's Equity Average history runs 5 years deep, the most recent figure standing at $17.2 million for Q1 2026.
- In Q1 2026, Equity Average fell 38.59% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $17.2 million (down 38.59% YoY), while the FY2025 annual figure was $18.9 million, down 17.33% from the prior year.
- Equity Average was $17.2 million for Q1 2026 at Genelux, up from $15.1 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $35.4 million in Q3 2024 to a low of -$34.1 million in Q4 2022.
- Historically, Equity Average has averaged $16.0 million across 5 years, with a median of $21.5 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Equity Average jumped 204.43% in 2024, then plunged 49.24% in 2025.
- A 5-year view of Equity Average shows it stood at -$34.1 million in 2022, then surged by 163.86% to $21.8 million in 2023, then soared by 36.47% to $29.7 million in 2024, then slumped by 49.24% to $15.1 million in 2025, then rose by 14.37% to $17.2 million in 2026.
- The last three Equity Average figures came in at $17.2 million (Q1 2026), $15.1 million (Q4 2025), and $21.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 17.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.23 Mn |
| Dec 31, 2025 | 15.07 Mn |
| Sep 30, 2025 | 21.24 Mn |
| Jun 30, 2025 | 26.87 Mn |
| Mar 31, 2025 | 28.06 Mn |
| Dec 31, 2024 | 29.68 Mn |
| Sep 30, 2024 | 35.38 Mn |
| Jun 30, 2024 | 26.38 Mn |
| Mar 31, 2024 | 17.28 Mn |
| Dec 31, 2023 | 21.75 Mn |
| Sep 30, 2023 | 23.14 Mn |
| Jun 30, 2023 | 12.47 Mn |
| Mar 31, 2023 | -16.55 Mn |
| Dec 31, 2022 | -34.06 Mn |